About US
Contact us
-
Don't confuse Kadcyla with Herceptin, FDA saysThe FDA is picky about drug names. It's been known to reject brand monikers because they're too similar to others already out there in the market, worried that harried physicians and pharmacists migh2013/5/8
-
Merck shows signs of life in consumer health with new promo campaignMerck & Co. hasn't spent huge amounts of time and resources pushing its consumer health business. While other Big Pharmas like Sanofi ($SNY) and GlaxoSmithKline ($GSK) went around the world snapp2013/5/8
-
ALM201 licensed to South Korean pharmaceutical for developmentThe novel anti-angiogenic peptide ALM2012 has been licensed to a South Korean pharmaceutical company for clinical development and marketing. That is according to a statement issued by the Northern Ir2013/5/7
-
Indian watchdogs pull J&J plant's license on baby-powder sterilization issueJohnson & Johnson is busy negotiating with Asian regulators these days. As FiercePharma reported Friday, South Korean regulators forced the company to halt production at an over-the-counter drug2013/5/7
-
GSK monitored parents' online vaccination discussions for 2 monthsGlaxoSmithKline ($GSK) has been listening to parents' concerns about childhood vaccinations. Really listening. In fact, it has used big data analytics to sift through thousands of comments from Inter2013/5/6
-
J&J issue in South Korea reminiscent of OTC problems hereDrugmakers hope to export their success to emerging markets so they can reap big rewards, but Johnson & Johnson's ($JNJ) Janssen unit appears to have taken a backward approach in South Korea, whe2013/5/6
-
Sanofi taps new EVPs in commercial operations re-orgSanofi ($SNY) is rejigging its commercial operations, with two new executive vice presidents stepping up to the plate to replace the retiring global operations President Hanspeter Spek. Peter Guenter2013/5/3
-
CFDA issues the First Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2013On April 19, 2013, China Food and Drug Administration (CFDA) issued the First Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2013.2013/5/3
-
Even if Actavis buy fails, Valeant looks ready for bigger dealsValeant ($VRX) CEO J. Michael Pearson hasn't made a secret of his ambitions. He wants to be within spitting distance of Big Pharma. Numbers-wise, that means he's shooting for $10 billion in sales, qu2013/5/2
-
First patient treated with new drug for multiple myelomaA patient suffering with multiple myeloma has been treated with a human antibody drug in a phase II clinical trial of BI-505 from BioInvent International. The drug binds to the ICAM-1 adhesion protein2013/5/2